Daily Brief Health Care: Astellas Pharma, Schott Pharma and more

• Astellas Pharma (4503 JP) reported ¥85B revenue increase in FY24 over FY23, while Fx impacted the revenue positively by ¥96B. In local currency terms, the U.S. revenue declined 5% YoY.
• FY24 operating and net profit declined 80%+, due to amortization and impairment loss of intangible assets. Astellas is changing accounting policy to smoothen core operating and net profits in FY25.
• For FY25, Astellas guided for just 3% revenue growth. Core operating profit is expected to decline 10%, while net profit is anticipated to take a bigger hit and decrease 17%.

• SCHOTT Pharma AG & Co. KGaA is experiencing accelerating growth in the pharmaceutical packaging industry due to the increasing prevalence of biologics, GLP-1s, and high value solutions.
• The company’s HVS segment is driving double-digit revenue growth and is expected to account for a larger percentage of total revenues in the future.
• With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand its market share.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.